Search

Your search keyword '"Costello, Régis"' showing total 320 results

Search Constraints

Start Over You searched for: Author "Costello, Régis" Remove constraint Author: "Costello, Régis"
320 results on '"Costello, Régis"'

Search Results

2. Correction: Efficient pathway for men fertility preservation in testicular cancer or lymphoma: a cross-sectional study of national 2018 data

3. Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial

4. Efficient pathway for men fertility preservation in testicular cancer or lymphoma: a cross-sectional study of national 2018 data

6. Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2.

8. Umbilical Cord Blood Transplantation for Fanconi Anemia With a Special Focus on Late Complications: a Study on Behalf of Eurocord and SAAWP-EBMT

10. Functional status in older patients with cancer

11. High Complete Metabolic Response Rates with Epcoritamab SC + GemOx in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2

17. P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL

22. Single-Cell Transcriptome Analysis of Acute Myeloid Leukemia Cells Using Methanol Fixation and Cryopreservation.

26. The contribution of multiplexing single cell RNA sequencing in acute myeloid leukemia

27. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO 16 LYMPHOVIR Cohort

29. Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm

31. Poster: ABCL-439 Subcutaneous Epcoritamab With Gemcitabine + Oxaliplatin (GemOx) Induced High Response Rates in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Autologous Stem Cell Transplant (ASCT)

33. ABCL-275 Epcoritamab + GemOx Induces Deep Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2

34. Epcoritamab + GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2

35. Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.

37. Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1 -Negative Myeloproliferative Neoplasm.

38. Characterization of the novel Sezary lymphoma cell line BKP1

39. Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia

40. Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma?—Potential therapeutic applications

41. HCV or HBV coinfection and lymphoma risk in people living with HIV

43. Contributors

48. High Serum Vitamin B12 Levels Associated with C-Reactive Protein in Older Patients with Cancer

50. Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

Catalog

Books, media, physical & digital resources